Genomic profiles of 108 tumors from stage I-IV SCLC showed 93% RB inactivation [9], but with rapidly growing malignancies, anything less than 100% RB inactivation may undermine chemotherapy's effectiveness in some cells; thereby antagonizing chemotherapy efficacy. The gene discussed is RB1; the disease is small cell lung carcinoma.